Request a copy

Full Text

• Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Secondline oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014;32:2423-2429.
• Chen LT, Von Hoff DD, Li CP, Wang-Gillam A, Bodoky G, Dean AP, et al. Expanded analysis of napoli-1: phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin in metastatic pancreatic cancer (mPAC) previously treated with gemcitabinebased therapy. J Clin Oncol 2015;33(Suppl):3.
• Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:2306-2314.
• Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30:1513-1518.
• Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an openlabel, phase 3 randomised controlled trial. Lancet Oncol 2014;15:78-86.
• Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs 2012;30:1216-1223.
• Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-39.
• Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224-1235.
• Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - a randomized, phase III study. J Clin Oncol 2014;32:2039-2049.
• Iacovelli R, Pietrantonio F, Farcomeni A, Maggi C, Palazzo A, Ricchini F, et al. Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. PLoS One 2014;9:e108940.
• Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
• Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumour regression without overt toxicity. J Clin Invest 2000;105:15-24.
• Romiti A, Cox MC, Sarcina I, Di Rocco R, D'Antonio C, Barucca V, et al. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother Pharmacol 2013;72:13-33.
• Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436.
• Hao YB, Yi SY, Ruanc J, Zhaob L, Nana KJ. New insights into metronomic chemotherapy-induced immunoregulation. Cancer Lett 2014;354:220-226.
• Steinbild S, Arends J, Medinger M, Häring B, Frost A, Drevs J, et al. Metronomic antiangiogenetic therapy with capecitabine and celecoxib in advanced tumour patients-results of a phase II study. Onkologie 2007;30:629-635.
• Young SD, Whissel M, Noble JC, Cano PO, Lopez PG, Germond CJ. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumours. Clin Cancer Res 2006;12:3092-3098.
• Allegrini G, Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, et al. Clinical pharmacokinetic and pharmacodynamics evaluation of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis 2012;15:275-286.
• He S, Shen J, Hong L, Niu L, Niu D. Capecitabine 'metronomic' chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy. Med Oncol 2012;29:100-106.
• Sun JF, Wu RR, Norris C, Noone AM, Amankwa-Sakyi M, Slack R, et al. Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers. Gastrointest Cancer Res 2009;3:134-140.
• Miger J, Holmqvist A, Sun XF, Albertsson M. Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer. Med Oncol 2014;31:870.
• Romiti A, Onesti CE, Roberto M, Barucca V, Tomao S, D'Antonio C, et al. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer. Med Oncol 2015;32:54.
• Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, et al. Safety and survival with GVAX pancreas prime and listeria monocytogenesexpressing mesothelin (CRS-207) boost vaccine for metastatic pancreatic cancer. J Clin Oncol 2015;33:1325-1333.
• Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4 +CD25 + regulatory T cells and restores T and NK effect or functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-648.
• Generali D, Bates G, Berruti A, Brizzi MP, Campo L, Bonardi S, et al. Immunomodulation of FOXP3 + regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res 2009;15:1046-1051.
• Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007;67:3560-3564.
• Lee KA, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 2009;106:2353-2358.
• Gaafar RM, Hussein MM, Ali Allahlo Aubi NM, Abdel Warith AM, Abd Allah WA, Salemet SE, et al. Toxicity and prediction of survival benefit with metronomic chemotherapy in metastatic breast cancer [abstract]. J Clin Oncol 2014;32(Suppl):5s.
• Dellapasqua S, Bagnardi V, Bertolini F, Sandri MT, Pastrello D, Cancello G, et al. Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. Breast 2012;21:309-313.
• Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and metaanalysis. J Clin Oncol 2014;32:1031-1039.
• Di Rocco R, Romiti A, Simmaco M, Barucca V, Toma S, D'antonio C, et al. TSER and MTHFR gene polymorphisms and toxicity in cancer patients treated with fluoropyrimidine based chemotherapy. Ann Oncol 2010;21(Suppl 6): viii248.